ClinicalTrials.gg
CompletedNCT00573794Updated Jul 7, 2021Results posted

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

A Phase 3 interventional study of adalimumab in Ulcerative Colitis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
592
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
2nd of 18
592 · median 152
Started
2007
the only one that year
Phase 3
10 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
3 of 18
AbbVie (prior sponsor, Abbott)

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 3, and was the 4th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have successfully enrolled and completed either study M06-826 (NCT00385736) or study M06-827 (NCT00408629)
  • Subject is judged to be in generally good health as determined by the principal investigator

Exclusion criteria

Exclusion Criteria:

  • Subject has not responded to weekly adalimumab therapy in M06-826 (NCT00385736) or M06-827 (NCT00408629)
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
592 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg EOW/EW

    Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    adalimumab prefilled syringes administered as subcutaneous injection EW or EOW

    Also known as: ABT-D2E7, HUMIRA

06

What researchers measure

Primary outcomes

  1. Partial Mayo Score: Change From Baseline Over Time

    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  2. Mayo Score: Change From Baseline Over Time

    The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

Secondary outcomes

  1. Percentage of Participants With Remission Per Partial Mayo Score Over Time

    The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore \> 1.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  2. Mayo Endoscopy Subscore: Change From Baseline Over Time

    The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  3. Mayo Rectal Bleeding Subscore: Change From Baseline Over Time

    The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  4. Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time

    The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  5. Mayo Stool Frequency Subscore: Change From Baseline Over Time

    The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  6. Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time

    The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  7. 36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  8. 36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  9. Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time

    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  10. WPAI:GH Impairment While Working: Change From Baseline Over Time

    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  11. WPAI:GH Overall Work Impairment: Change From Baseline Over Time

    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  12. WPAI:GH Activity Impairment: Change From Baseline Over Time

    The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

    Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388

  13. Colectomy Rate

    The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.

    Time frame: 5 years

  14. Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations

    The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.

    Time frame: 5 years

  15. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

    Time frame: From first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks)

  16. Hematology: Mean Change From Baseline to Final Values in Hemoglobin

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  17. Hematology: Mean Change From Baseline to Final Values in Hematocrit

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  18. Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  19. Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  20. Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  21. Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  22. Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

  23. Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein

    Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

    Time frame: Baseline (Week 0), final value (up to 5 years)

07

Results

Posted Dec 19, 2017
Limitations and caveats
Efficacy data after Week 292 should be interpreted with caution because less than 10% of subjects were under observation beyond Week 292.

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 40 mg EOW/EW
Started585
Completed255
Not completed330
Withdrew: Adverse event81
Withdrew: Withdrew consent90
Withdrew: Lost to follow-up13
Withdrew: Protocol violation6
Withdrew: Lack of efficacy94
Withdrew: Other46

Outcome measures

PrimaryPartial Mayo Score: Change From Baseline Over Time

The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Partial Mayo Score: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline2.5 ± 2.02
Change from Baseline to Week 48-0.2 ± 2.04
Change from Baseline to Week 96-0.4 ± 1.78
Change from Baseline to Week 144-0.5 ± 2.06
Change from Baseline to Week 192-0.6 ± 1.84
Change from Baseline to Week 240-0.8 ± 1.79
Change from Baseline to Week 292-0.7 ± 2.05
Change from Baseline to Week 340-1.0 ± 1.97
Change from Baseline to Week 388-2.0 ± 1.00
PrimaryMayo Score: Change From Baseline Over Time

The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Mayo Score: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline3.5 ± 2.72
Change from Baseline to Week 48-0.3 ± 2.64
Change from Baseline to Week 96-0.5 ± 2.49
Change from Baseline to Week 144-0.8 ± 2.73
Change from Baseline to Week 192-0.8 ± 2.52
Change from Baseline to Week 240-1.0 ± 2.40
Change from Baseline to Week 292-0.9 ± 2.84
Change from Baseline to Week 340-1.3 ± 2.87
Change from Baseline to Week 388-2.0 ± 1.73
SecondaryPercentage of Participants With Remission Per Partial Mayo Score Over Time

The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore \> 1.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Number · percentage of participants
Percentage of Participants With Remission Per Partial Mayo Score Over Time
percentage of participantsAdalimumab 40 mg EOW/EW
Baseline52.4
Week 4861.2
Week 9669.3
Week 14475.0
Week 19274.7
Week 24077.2
Week 29276.7
Week 34073.9
Week 388100
SecondaryMayo Endoscopy Subscore: Change From Baseline Over Time

The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Mayo Endoscopy Subscore: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline1.1 ± 0.94
Change from Baseline to Week 48-0.1 ± 0.95
Change from Baseline to Week 96-0.1 ± 1.02
Change from Baseline to Week 144-0.2 ± 0.93
Change from Baseline to Week 192-0.3 ± 0.98
Change from Baseline to Week 240-0.3 ± 0.97
Change from Baseline to Week 292-0.3 ± 1.03
Change from Baseline to Week 340-0.3 ± 1.18
Change from Baseline to Week 3880.0 ± 1.00
SecondaryMayo Rectal Bleeding Subscore: Change From Baseline Over Time

The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Mayo Rectal Bleeding Subscore: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline0.4 ± 0.68
Change from Baseline to Week 48-0.1 ± 0.73
Change from Baseline to Week 96-0.0 ± 0.63
Change from Baseline to Week 144-0.1 ± 0.74
Change from Baseline to Week 192-0.1 ± 0.69
Change from Baseline to Week 240-0.2 ± 0.63
Change from Baseline to Week 292-0.2 ± 0.76
Change from Baseline to Week 340-0.2 ± 0.80
Change from Baseline to Week 388-1.0 ± 1.00
SecondaryMayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time

The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline0.8 ± 0.81
Change from Baseline to Week 48-0.1 ± 0.89
Change from Baseline to Week 96-0.2 ± 0.84
Change from Baseline to Week 144-0.2 ± 0.89
Change from Baseline to Week 192-0.2 ± 0.82
Change from Baseline to Week 240-0.3 ± 0.82
Change from Baseline to Week 292-0.2 ± 0.79
Change from Baseline to Week 340-0.3 ± 0.88
Change from Baseline to Week 388-0.7 ± 0.58
SecondaryMayo Stool Frequency Subscore: Change From Baseline Over Time

The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Mayo Stool Frequency Subscore: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline1.3 ± 1.01
Change from Baseline to Week 48-0.1 ± 0.89
Change from Baseline to Week 96-0.2 ± 0.84
Change from Baseline to Week 144-0.2 ± 0.89
Change from Baseline to Week 192-0.2 ± 0.82
Change from Baseline to Week 240-0.3 ± 0.86
Change from Baseline to Week 292-0.3 ± 1.00
Change from Baseline to Week 340-0.5 ± 0.99
Change from Baseline to Week 388-0.3 ± 0.58
SecondaryInflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time

The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline176.0 ± 34.45
Change from Baseline to Week 482.1 ± 28.91
Change from Baseline to Week 964.7 ± 28.73
Change from Baseline to Week 1445.2 ± 30.64
Change from Baseline to Week 1927.6 ± 28.66
Change from Baseline to Week 24011.2 ± 25.98
Change from Baseline to Week 29214.8 ± 27.36
Change from Baseline to Week 34014.6 ± 28.12
Change from Baseline to Week 38811.0 ± 12.53
Secondary36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline47.1 ± 10.16
Change from Baseline to Week 48-0.7 ± 9.61
Change from Baseline to Week 960.3 ± 9.64
Change from Baseline to Week 1440.0 ± 9.52
Change from Baseline to Week 1920.1 ± 9.41
Change from Baseline to Week 2400.7 ± 7.86
Change from Baseline to Week 2921.8 ± 8.13
Change from Baseline to Week 3401.8 ± 6.81
Change from Baseline to Week 388-7.3 ± 5.58
Secondary36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · units on a scale
36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time
units on a scaleAdalimumab 40 mg EOW/EW
Baseline49.3 ± 8.06
Change from Baseline to Week 480.7 ± 6.98
Change from Baseline to Week 961.2 ± 6.26
Change from Baseline to Week 1441.1 ± 7.08
Change from Baseline to Week 1921.3 ± 7.46
Change from Baseline to Week 2402.2 ± 6.23
Change from Baseline to Week 2922.5 ± 7.03
Change from Baseline to Week 3403.0 ± 8.71
Change from Baseline to Week 3888.4 ± 2.00
SecondaryWork Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time

The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · percent of work time missed
Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time
percent of work time missedAdalimumab 40 mg EOW/EW
Baseline4.5 ± 15.42
Change from Baseline to Week 481.6 ± 24.04
Change from Baseline to Week 96-0.2 ± 18.41
Change from Baseline to Week 1440.9 ± 20.19
Change from Baseline to Week 1920.2 ± 19.05
Change from Baseline to Week 240-1.1 ± 17.21
Change from Baseline to Week 2928.2 ± 30.65
Change from Baseline to Week 3406.4 ± 24.96
Change from Baseline to Week 3880.0 ± 0.00
SecondaryWPAI:GH Impairment While Working: Change From Baseline Over Time

The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · percent of work time impaired
WPAI:GH Impairment While Working: Change From Baseline Over Time
percent of work time impairedAdalimumab 40 mg EOW/EW
Baseline16.7 ± 20.73
Change from Baseline to Week 481.1 ± 22.45
Change from Baseline to Week 96-1.9 ± 20.86
Change from Baseline to Week 144-0.2 ± 24.11
Change from Baseline to Week 192-2.9 ± 24.04
Change from Baseline to Week 240-4.0 ± 21.40
Change from Baseline to Week 292-3.8 ± 25.45
Change from Baseline to Week 340-13.8 ± 26.04
Change from Baseline to Week 388-15.0 ± 21.21
SecondaryWPAI:GH Overall Work Impairment: Change From Baseline Over Time

The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · percent of overall work impairment
WPAI:GH Overall Work Impairment: Change From Baseline Over Time
percent of overall work impairmentAdalimumab 40 mg EOW/EW
Baseline20.1 ± 24.30
Change from Baseline to Week 481.2 ± 28.15
Change from Baseline to Week 96-2.7 ± 24.99
Change from Baseline to Week 144-0.8 ± 28.05
Change from Baseline to Week 192-2.6 ± 26.69
Change from Baseline to Week 240-5.0 ± 24.1
Change from Baseline to Week 2921.4 ± 35.53
Change from Baseline to Week 340-7.3 ± 12.05
Change from Baseline to Week 388-15.0 ± 21.21
SecondaryWPAI:GH Activity Impairment: Change From Baseline Over Time

The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.

Time frame:
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Reported as:
Mean · percent activity impaired
WPAI:GH Activity Impairment: Change From Baseline Over Time
percent activity impairedAdalimumab 40 mg EOW/EW
Baseline21.4 ± 24.00
Change from Baseline to Week 481.1 ± 24.14
Change from Baseline to Week 96-1.6 ± 21.80
Change from Baseline to Week 144-0.7 ± 23.65
Change from Baseline to Week 192-2.1 ± 20.91
Change from Baseline to Week 240-3.4 ± 18.63
Change from Baseline to Week 292-1.5 ± 19.79
Change from Baseline to Week 340-9.6 ± 11.86
Change from Baseline to Week 388-16.7 ± 15.28
SecondaryColectomy Rate

The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.

Time frame:
5 years
Reported as:
Number · percentage of participants
Colectomy Rate
percentage of participantsAdalimumab 40 mg EOW/EW
Colectomy Rate3.88
SecondaryHealth Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations

The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.

Time frame:
5 years
Reported as:
Number · cumulative number of utilizations
Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations
cumulative number of utilizationsAdalimumab 40 mg EOW/EW
Physician561
Emergency Room43
Hospital Admission65
Days in Hospital435
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

Time frame:
From first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsAdalimumab 40 mg EOW/EW
Any TEAE496
Any TESAE158
SecondaryHematology: Mean Change From Baseline to Final Values in Hemoglobin

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · g/L
Hematology: Mean Change From Baseline to Final Values in Hemoglobin
g/LAdalimumab 40 mg EOW/EW
Hematology: Mean Change From Baseline to Final Values in Hemoglobin-0.1 ± 16.02
SecondaryHematology: Mean Change From Baseline to Final Values in Hematocrit

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · Percentage of red blood cells
Hematology: Mean Change From Baseline to Final Values in Hematocrit
Percentage of red blood cellsAdalimumab 40 mg EOW/EW
Hematology: Mean Change From Baseline to Final Values in Hematocrit0.013 ± 0.0472
SecondaryHematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · cells * 10^9/L
Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils
cells * 10^9/LAdalimumab 40 mg EOW/EW
Red blood cell count0.03 ± 0.416
Platelet count-10.5 ± 96.98
White blood cell count0.41 ± 2.704
Neutrophils0.164 ± 2.4225
Lymphocytes0.155 ± 0.8270
Monocytes0.051 ± 0.2203
Eosinophils0.002 ± 0.1602
Basophils0.009 ± 0.0586
SecondaryClinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · U/L
Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase
U/LAdalimumab 40 mg EOW/EW
Alanine aminotransferase3.7 ± 22.03
Aspartate aminotransferase2.6 ± 28.13
Alkaline phosphatase-0.2 ± 34.65
SecondaryClinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · μmol/L
Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid
μmol/LAdalimumab 40 mg EOW/EW
Total bilirubin-1.0 ± 5.35
Creatinine2.4 ± 13.18
Uric acid7.6 ± 65.52
SecondaryClinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · mmol/L
Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides
mmol/LAdalimumab 40 mg EOW/EW
Blood urea nitrogen0.32 ± 1.409
Inorganic phosphate-0.003 ± 0.2312
Calcium-0.012 ± 0.1185
Sodium-0.0 ± 2.49
Potassium0.07 ± 0.424
Glucose0.05 ± 1.334
Cholesterol-0.025 ± 0.8853
Triglycerides0.178 ± 1.2800
SecondaryClinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · g/L
Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein
g/LAdalimumab 40 mg EOW/EW
Albumin-0.4 ± 3.85
Total protein0.7 ± 18.99
SecondaryClinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein

Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.

Time frame:
Baseline (Week 0), final value (up to 5 years)
Reported as:
Mean · mg/L
Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein
mg/LAdalimumab 40 mg EOW/EW
Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein0.382 ± 15.1489

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg EOW/EW—158/592 (26.7%)391/592 (66%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventAdalimumab 40 mg EOW/EW
COLITIS ULCERATIVEGastrointestinal disorders34/592
PNEUMONIAInfections and infestations11/592
ANAEMIABlood and lymphatic system disorders6/592
APPENDICITISInfections and infestations5/592
OSTEOARTHRITISMusculoskeletal and connective tissue disorders5/592
COLITISGastrointestinal disorders3/592
ANAL ABSCESSInfections and infestations3/592
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders3/592
B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)3/592
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)3/592
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAdalimumab 40 mg EOW/EW
COLITIS ULCERATIVEGastrointestinal disorders180/592
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations115/592
ARTHRALGIAMusculoskeletal and connective tissue disorders62/592
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations58/592
SINUSITISInfections and infestations53/592
DIARRHOEAGastrointestinal disorders46/592
HEADACHENervous system disorders46/592
INFLUENZAInfections and infestations42/592
RASHSkin and subcutaneous tissue disorders42/592
COUGHRespiratory, thoracic and mediastinal disorders41/592

Baseline characteristics

ITT-1: All subjects who received ≥1 dose of study drug excluding 7 subjects at noncompliant sites.

Age, Continuous
Age, Continuous(years)Adalimumab 40 mg EOW/EW
Mean41.6 ± 12.85
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg EOW/EW
Female214
Male371
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26. PubMed 25155227 ↗
  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Dec 2016, 109 months.

Results were first posted in Dec 2017, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 109 months is above that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2007
First posted
Dec 14, 2007
StartActual
Nov 28, 2007
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
Dec 19, 2017
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00573794
Responsible party
Sponsor
First posted
Dec 14, 2007
Start date
Nov 28, 2007
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Dec 19, 2017
Last update
Jul 7, 2021

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion